Pigmented Lesion Clinic and Cutaneous Oncology Program, Department of Dermatology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.
JAMA Dermatol. 2018 Dec 1;154(12):1401-1408. doi: 10.1001/jamadermatol.2018.3359.
Little evidence exists to guide the management of moderately dysplastic nevi excisionally biopsied without residual clinical pigmentation but with positive histologic margins (hereafter referred to as moderately dysplastic nevi with positive histologic margins).
To determine outcomes and risk for the development of subsequent cutaneous melanoma (CM) from moderately dysplastic nevi with positive histologic margins observed for 3 years or more.
DESIGN, SETTING, AND PARTICIPANTS: A multicenter (9 US academic dermatology sites) retrospective cohort study was conducted of patients 18 years or older with moderately dysplastic nevi with positive histologic margins and 3 years or more of follow-up data collected consecutively from January 1, 1990, to August 31, 2014. Records were reviewed for patient demographics, biopsy type, pathologic findings, and development of subsequent CM at the biopsy site or elsewhere on the body. The χ2 test, the Fisher exact test, and analysis of variance were used to assess univariate association for risk of subsequent CMs, in addition to multivariable logistic regression models. To confirm histologic grading, each site submitted 5 random representative slide cases for central dermatopathologic review. Statistical analysis was performed from October 1, 2017, to June 22, 2018.
Development of CM at a biopsy site or elsewhere on the body where there were moderately dysplastic nevi with positive histologic margins.
A total of 467 moderately dysplastic nevi with positive histologic margins from 438 patients (193 women and 245 men; mean [SD] age, 46.7 [16.1] years) were evaluated. No cases developed into CM at biopsy sites, with a mean (SD) follow-up time of 6.9 (3.4) years. However, 100 patients (22.8%) developed a CM at a separate site. Results of multivariate analyses revealed that history of CM was significantly associated with the risk of development of subsequent CM at a separate site (odds ratio, 11.74; 95% CI, 5.71-24.15; P < .001), as were prior biopsied dysplastic nevi (odds ratio, 2.55; 95% CI, 1.23-5.28; P = .01). The results of a central dermatopathologic review revealed agreement in 35 of 40 cases (87.5%). Three of 40 cases (7.5%) were upgraded in degree of atypia; of these, 1 was interpreted as melanoma in situ. That patient remains without recurrence or evidence of CM after 5 years of follow-up.
This study suggests that close observation with routine skin surveillance is a reasonable management approach for moderately dysplastic nevi with positive histologic margins. However, having 2 or more biopsied dysplastic nevi (with 1 that is a moderately dysplastic nevus) appears to be associated with increased risk for subsequent CM at a separate site.
对于无残余临床色素沉着但组织学边缘阳性(以下简称组织学边缘阳性中度不典型痣)的中度不典型痣行切除活检,目前几乎没有证据可以指导其治疗。
确定组织学边缘阳性的中度不典型痣在观察 3 年或更长时间后的结局和发展为后续皮肤黑色素瘤(CM)的风险。
设计、地点和参与者:这是一项多中心(美国 9 个学术皮肤科地点)回顾性队列研究,纳入了 18 岁及以上、组织学边缘阳性且有 3 年或更长随访数据的中度不典型痣患者。从 1990 年 1 月 1 日至 2014 年 8 月 31 日,连续收集患者的人口统计学资料、活检类型、病理发现和活检部位或身体其他部位发展为后续 CM 的情况。使用卡方检验、Fisher 确切检验和方差分析评估后续 CM 风险的单变量关联,以及多变量逻辑回归模型。为了确认组织学分级,每个地点提交了 5 份随机代表病例进行中心皮肤病理复查。统计分析于 2017 年 10 月 1 日至 2018 年 6 月 22 日进行。
在组织学边缘阳性的中度不典型痣存在的活检部位或身体其他部位发展为 CM。
共评估了 438 例患者的 467 个组织学边缘阳性的中度不典型痣(193 名女性和 245 名男性;平均[标准差]年龄为 46.7[16.1]岁)。没有病例在活检部位发展为 CM,平均(标准差)随访时间为 6.9(3.4)年。然而,有 100 例(22.8%)患者在其他部位发生了 CM。多变量分析结果显示,CM 病史与在其他部位发生后续 CM 的风险显著相关(比值比,11.74;95%CI,5.71-24.15;P<0.001),既往活检的不典型痣(比值比,2.55;95%CI,1.23-5.28;P=0.01)也是如此。中心皮肤病理复查结果显示,40 例中有 35 例(87.5%)的结果一致。有 3 例(7.5%)病例的异型性程度升级;其中 1 例被诊断为原位黑色素瘤。该患者在 5 年随访后仍无复发或 CM 证据。
这项研究表明,对于组织学边缘阳性的中度不典型痣,密切观察和常规皮肤监测是一种合理的治疗方法。然而,有 2 个或更多活检的不典型痣(其中 1 个为中度不典型痣)似乎与在其他部位发生后续 CM 的风险增加相关。